China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has ...

Minnesota Alzheimer's patients will be among the first to receive a new treatment through the drug Kisunla, which targets the ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The ...

FOX 9 caught up with a Minnesota woman undergoing a new Alzheimer’s treatment which is showing promise in slowing cognitive ...

The company states: “Eli Lilly (LLY) announced that the National Medical Products Administration in China has approved Kisunla, an Alzheimer’s treatment for adults with early symptomatic Alzheimer’s ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Eli Lilly and Co. (LLY) said that the National Medical Products Administration (NMPA) in China has approved Kisunla (donanemab-azbt, ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

Eli Lilly and Company today announced that the National Medical Products Administration (NMPA) in China has approved Kisunlatm (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion) ...